AmpliPhi Biosciences Corporation (NYSE MKT:APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an underwritten public offering of 6,956,522 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and common warrants to purchase up to an aggregate of 6,956,522 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $1.50 per share and accompanying common warrant. For each pre-funded warrant AmpliPhi sells, the number of shares of common stock AmpliPhi is offering will be decreased on a one-for-one basis.
AmpliPhi Biosciences Corporation stock had a weekly Volatility of 53.15% and a monthly volatility of 24.38%. AmpliPhi Biosciences Corporation APHB shares float stands at 1.47M.
AmpliPhi Biosciences Corporation quarterly Return on Assets is -95.40%%, quarterly Return on Equity was -166.50%% while quarterly Return on Investments was -217.40%%.
The company’s Total Debt/Equity stood at 0.08.
The company’s stock 50-Day High is $-42.00% and a 50-Day Low of $861.22%. 20-Day Simple Moving Average was $156.88% while 50-Day Simple Moving Average was $292.75%.
The company announced EPS of $-25.71. This represents an EPS growth quarter over quarter of -29.80%%. EPS for the whole years was $-23.70%. For the last five years, the stock has reported an average EPS growth of 10.30%% and EPS growth for next year is projected to be -5.70%%.
The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
The company’s monthly average volume for the quarter was 347.75K and 347.75K for the full financial year. The relative volume was 31.09 for the quarter and 31.09 for the full financial year.
The stock’s 50-Day High during the quarter was $-42.00% while the 50-Day Low was $861.22%. In the last financial year, the stock has a 52-Week High of $-42.00% and a 52-Week Low of $861.22%.
The company’s Insider Ownership was 0.10% and Institutional Ownership was 21.20%. Total Institutional Transactions amounted to -0.09%. Sales growth quarter over quarter was -82.80%%.